Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.

Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog (2017) 0.75

Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance. PLoS One (2016) 0.75

Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus. PLoS One (2017) 0.75

MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol (2013) 112.81

The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci (1992) 44.38

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87

Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50

Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol (2000) 3.26

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93

Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85

Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24

Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 2.06

Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79

Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77

Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72

Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66

Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65

Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature (2014) 1.64

Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol (2008) 1.63

Cell entry of hepatitis C virus. Virology (2006) 1.58

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53

Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J (2013) 1.52

The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut (2001) 1.51

Hepatitis C virus host cell entry. Curr Opin Virol (2012) 1.41

Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37

Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 1.29

Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS (2009) 1.28

Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis (2012) 1.24

Hepatitis C virus entry: beyond receptors. Rev Med Virol (2012) 1.23

Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22

Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol (2006) 1.18

Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol (2011) 1.17

Best strategies for global HCV eradication. Liver Int (2013) 1.16

Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13

Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. J Virol (2011) 1.07

A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res (2009) 1.05

Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99

Human lymphocyte repertoires in ageing. Curr Opin Immunol (2013) 0.98

Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM (1999) 0.97

The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev (2007) 0.94

The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. J Gen Virol (2010) 0.89

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology (2014) 0.89

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol (2008) 0.89

Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Res (2012) 0.87

Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol (2007) 0.85

Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses (2009) 0.84

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. J Virol (2015) 0.83

Genome-wide association study of rheumatoid arthritis by a score test based on wavelet transformation. BMC Proc (2009) 0.83

Elevated interferon-stimulated gene transcription in peripheral blood mononuclear cells occurs in patients infected with genotype 1 but not genotype 3 hepatitis C virus. J Viral Hepat (2014) 0.81

Combinatorial library-based profiling of the antibody response against hepatitis C virus in humans. J Gen Virol (2014) 0.78

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease. J Viral Hepat (2008) 0.78

Claudin-1 and its potential role in HCV entry: another piece of the puzzle. J Clin Gastroenterol (2008) 0.77

Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy. Immunol Lett (1997) 0.77